Mustang Bio Inc.

1.35
-0.09 (-6.25%)
At close: Apr 03, 2025, 3:59 PM
1.30
-3.70%
After-hours: Apr 03, 2025, 04:55 PM EDT
-6.25%
Bid 1.28
Market Cap 4.46M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -1928.5
PE Ratio (ttm) n/a
Forward PE -0.24
Analyst Buy
Ask 1.5
Volume 125,835
Avg. Volume (20D) 233,115
Open 1.34
Previous Close 1.44
Day's Range 1.27 - 1.38
52-Week Range 1.20 - 65.00
Beta 1.81

About MBIO

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develo...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 22, 2017
Employees 80
Stock Exchange NASDAQ
Ticker Symbol MBIO
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for MBIO stock is "Buy." The 12-month stock price forecast is $100, which is an increase of 7307.96% from the latest price.

Stock Forecasts
1 month ago
-27.01%
Mustang Bio shares are trading lower after the com... Unlock content with Pro Subscription
1 month ago
-1.02%
Mustang Bio shares are trading higher after the company announced it regained compliance with Nasdaq regarding its minimum bid price requirements.